152 related articles for article (PubMed ID: 35441784)
21. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
[TBL] [Abstract][Full Text] [Related]
22. Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma.
Bona K; Li Y; Winestone LE; Getz KD; Huang YS; Fisher BT; Desai AV; Richardson T; Hall M; Naranjo A; Henderson TO; Aplenc R; Bagatell R
J Natl Cancer Inst; 2021 Mar; 113(3):282-291. PubMed ID: 33227816
[TBL] [Abstract][Full Text] [Related]
23. Level of Seven Neuroblastoma-Associated mRNAs Detected by Droplet Digital PCR Is Associated with Tumor Relapse/Regrowth of High-Risk Neuroblastoma Patients.
Thwin KKM; Ishida T; Uemura S; Yamamoto N; Lin KS; Tamura A; Kozaki A; Saito A; Kishimoto K; Mori T; Hasegawa D; Kosaka Y; Nino N; Takafuji S; Iijima K; Nishimura N
J Mol Diagn; 2020 Feb; 22(2):236-246. PubMed ID: 31837427
[TBL] [Abstract][Full Text] [Related]
24. [Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children].
Fan HJ; Huang C; Su Y; Wang XD; Zhou YC; Duan C; Zhao W; Zhao Q; Jin M; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):863-869. PubMed ID: 31665841
[No Abstract] [Full Text] [Related]
25. Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study.
Morgenstern DA; Pötschger U; Moreno L; Papadakis V; Owens C; Ash S; Pasqualini C; Luksch R; Garaventa A; Canete A; Elliot M; Wieczorek A; Laureys G; Kogner P; Malis J; Ruud E; Beck-Popovic M; Schleiermacher G; Valteau-Couanet D; Ladenstein R
Pediatr Blood Cancer; 2018 Nov; 65(11):e27363. PubMed ID: 30015396
[TBL] [Abstract][Full Text] [Related]
26. Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.
Hoon DS; Kuo CT; Wen S; Wang H; Metelitsa L; Reynolds CP; Seeger RC
Am J Pathol; 2001 Aug; 159(2):493-500. PubMed ID: 11485908
[TBL] [Abstract][Full Text] [Related]
27. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
[TBL] [Abstract][Full Text] [Related]
28. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].
Su Y; Ma XL; Wang HM; Qin H; Qin MQ; Zhang FQ; Jin M; Zhang DW; Chen CH; Zeng Q; He LJ; Ni X
Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):796-801. PubMed ID: 32987457
[No Abstract] [Full Text] [Related]
29. Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma.
Yáñez Y; Grau E; Oltra S; Cañete A; Martínez F; Orellana C; Noguera R; Palanca S; Castel V
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1263-72. PubMed ID: 21706131
[TBL] [Abstract][Full Text] [Related]
30. Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report.
Pinto N; Naranjo A; Ding X; Zhang FF; Hibbitts E; Kennedy R; Tibbetts R; Wong-Michalak S; Craig DW; Manojlovic Z; Hogarty MD; Kreissman S; Bagatell R; Irwin MS; Park JR; Asgharzadeh S
Clin Cancer Res; 2023 Apr; 29(8):1546-1556. PubMed ID: 36749880
[TBL] [Abstract][Full Text] [Related]
31. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
32. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study.
Seeger RC; Reynolds CP; Gallego R; Stram DO; Gerbing RB; Matthay KK
J Clin Oncol; 2000 Dec; 18(24):4067-76. PubMed ID: 11118468
[TBL] [Abstract][Full Text] [Related]
33. [Long-term follow-up of neuroblastoma in children less than 18 months of age].
Zhao J; Pan C; Xu M; Zhou M; Gao YJ; Hu WT; Tang JY
Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):754-759. PubMed ID: 29050113
[No Abstract] [Full Text] [Related]
34. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study.
Maris JM; Weiss MJ; Guo C; Gerbing RB; Stram DO; White PS; Hogarty MD; Sulman EP; Thompson PM; Lukens JN; Matthay KK; Seeger RC; Brodeur GM
J Clin Oncol; 2000 May; 18(9):1888-99. PubMed ID: 10784629
[TBL] [Abstract][Full Text] [Related]
35. Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group.
Teshiba R; Kawano S; Wang LL; He L; Naranjo A; London WB; Seeger RC; Gastier-Foster JM; Look AT; Hogarty MD; Cohn SL; Maris JM; Park JR; Shimada H
Pediatr Dev Pathol; 2014; 17(6):441-9. PubMed ID: 25207821
[TBL] [Abstract][Full Text] [Related]
36. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies.
Stram DO; Matthay KK; O'Leary M; Reynolds CP; Haase GM; Atkinson JB; Brodeur GM; Seeger RC
J Clin Oncol; 1996 Sep; 14(9):2417-26. PubMed ID: 8823319
[TBL] [Abstract][Full Text] [Related]
37. Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.
Cheung IY; Feng Y; Gerald W; Cheung NK
Clin Cancer Res; 2008 Nov; 14(21):7020-7. PubMed ID: 18980998
[TBL] [Abstract][Full Text] [Related]
38. Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma.
van Wezel EM; Stutterheim J; Vree F; Zappeij-Kannegieter L; Decarolis B; Hero B; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; Voermans C; van Noesel MM; Caron HN; van der Schoot CE; Tytgat GA;
Pediatr Blood Cancer; 2015 Aug; 62(8):1368-73. PubMed ID: 25939774
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma.
Hero B; Hunneman DH; Gahr M; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):220-3. PubMed ID: 11464889
[TBL] [Abstract][Full Text] [Related]
40. Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification.
Bender HG; Irwin MS; Hogarty MD; Castleberry R; Maris JM; Kao PC; Zhang FF; Naranjo A; Cohn SL; London WB
J Clin Oncol; 2023 Jun; 41(17):3149-3159. PubMed ID: 37098238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]